CDX ( DrugBank: - )


2 diseases
IDDisease name (Link within this page)Number of trials
222Primary nephrotic syndrome1
240Phenylketonuria2

222. Primary nephrotic syndrome


Clinical trials : 285 Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01791686
(ClinicalTrials.gov)
January 201329/1/2013Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit DiseaseA Pilot, Open-label, Multicenter Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit DiseaseDense Deposit Disease;Membranoproliferative Glomerulonephritis Type II;C3 GlomerulonephritisDrug: CDX-1135Celldex TherapeuticsNULLTerminated4 YearsN/ABoth1Phase 1United States

240. Phenylketonuria


Clinical trials : 138 Drugs : 106 - (DrugBank : 11) / Drug target gene : 1 - Drug target pathways : 5
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04256655
(ClinicalTrials.gov)
December 1, 202028/1/2020Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of CDX 6114 in PKU PatientsA Phase 1, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of CDX 6114 After Multiple Ascending Oral Dose Administration to Patients With Phenylketonuria (PKU).PhenylketonuriasDrug: cohort 1 0.225g;Drug: Cohort 2 0.75g;Drug: Cohort 3 2.25 gNestléNULLWithdrawn18 Years65 YearsAll0Phase 1NULL
2NCT04085666
(ClinicalTrials.gov)
June 1, 20193/8/2019Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of CDX-6114 in Patients With Phenylketonuria (PKU)A Phase 1, Multi-center, Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of a Single Oral Dose of CDX-6114 in Patients With Phenylketonuria (PKU).PhenylketonuriaDrug: CDX 6114;Other: Matching PlaceboNestléNULLCompleted18 Years55 YearsAll18Phase 1Australia;Germany